NewAmsterdam Pharma (NAMS) Competitors $22.56 -0.85 (-3.63%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$22.38 -0.17 (-0.78%) As of 03/26/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. ASND, SRPT, PCVX, QGEN, ROIV, RVMD, LNTH, LEGN, TGTX, and BBIOShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), TG Therapeutics (TGTX), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Ascendis Pharma A/S Sarepta Therapeutics Vaxcyte Qiagen Roivant Sciences Revolution Medicines Lantheus Legend Biotech TG Therapeutics BridgeBio Pharma Ascendis Pharma A/S (NASDAQ:ASND) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment. Does the MarketBeat Community favor ASND or NAMS? Ascendis Pharma A/S received 421 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.30% of users gave NewAmsterdam Pharma an outperform vote while only 66.82% of users gave Ascendis Pharma A/S an outperform vote. CompanyUnderperformOutperformAscendis Pharma A/SOutperform Votes44766.82% Underperform Votes22233.18% NewAmsterdam PharmaOutperform Votes2696.30% Underperform Votes13.70% Do institutionals and insiders believe in ASND or NAMS? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer ASND or NAMS? Ascendis Pharma A/S presently has a consensus target price of $204.64, indicating a potential upside of 29.29%. NewAmsterdam Pharma has a consensus target price of $43.33, indicating a potential upside of 92.08%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, ASND or NAMS? NewAmsterdam Pharma has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$363.64M26.42-$409.12M-$7.10-22.29NewAmsterdam Pharma$45.56M54.38-$176.94M-$2.60-8.68 Which has more risk and volatility, ASND or NAMS? Ascendis Pharma A/S has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Is ASND or NAMS more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -104.54%. Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-104.54% N/A -39.23% NewAmsterdam Pharma N/A N/A N/A Does the media refer more to ASND or NAMS? In the previous week, Ascendis Pharma A/S had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.21 beat Ascendis Pharma A/S's score of 1.02 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNewAmsterdam Pharma beats Ascendis Pharma A/S on 11 of the 17 factors compared between the two stocks. Remove Ads Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.48B$6.90B$5.62B$8.13BDividend YieldN/A2.73%4.56%4.00%P/E Ratio-8.687.1824.5419.09Price / Sales54.38226.87386.7694.71Price / CashN/A65.6738.1634.64Price / Book6.456.486.974.36Net Income-$176.94M$142.41M$3.20B$247.23M7 Day Performance-6.27%-2.89%-2.19%-0.34%1 Month Performance7.89%-4.52%3.14%-3.60%1 Year Performance-0.62%-8.69%11.39%2.01% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma2.3534 of 5 stars$22.56-3.6%$43.33+92.1%-0.7%$2.48B$45.56M-8.684Short Interest ↑Positive NewsHigh Trading VolumeASNDAscendis Pharma A/S2.946 of 5 stars$168.84+10.4%$202.36+19.9%+5.5%$10.25B$363.64M-23.781,017Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.8507 of 5 stars$101.35+4.3%$170.41+68.1%-43.2%$9.83B$1.90B81.081,314PCVXVaxcyte2.0514 of 5 stars$75.23+1.2%$147.50+96.1%+1.7%$9.69BN/A-16.35160Positive NewsQGENQiagen3.6996 of 5 stars$39.85+0.9%$47.71+19.7%-4.7%$8.84B$1.98B110.956,030Short Interest ↑ROIVRoivant Sciences2.3562 of 5 stars$10.85+1.8%$18.08+66.7%+3.6%$7.74B$122.59M-72.33860Insider TradePositive NewsRVMDRevolution Medicines4.1302 of 5 stars$39.13+0.0%$66.31+69.5%+25.7%$7.27B$742,000.00-10.90250Positive NewsLNTHLantheus4.277 of 5 stars$102.76+1.6%$132.86+29.3%+67.5%$7.04B$1.53B17.10700Analyst RevisionLEGNLegend Biotech2.9144 of 5 stars$37.94+2.0%$79.17+108.7%-38.0%$6.93B$627.24M-39.941,800Short Interest ↓Positive NewsTGTXTG Therapeutics3.0477 of 5 stars$41.06+0.5%$40.67-1.0%+164.2%$6.45B$329.00M-410.56290Positive NewsBBIOBridgeBio Pharma4.6889 of 5 stars$33.01+0.1%$51.55+56.2%+21.3%$6.28B$221.90M-11.58400Analyst ForecastPositive News Remove Ads Related Companies and Tools Related Companies Ascendis Pharma A/S Alternatives Sarepta Therapeutics Alternatives Vaxcyte Alternatives Qiagen Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Lantheus Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives BridgeBio Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.